| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Outline of Final Research Achievements |
Cell therapy for rheumatoid arthritis and osteoarthritis is becoming important recently. One of the treatment method is human mesenchymal stem cells (hMSCs). Inflammatory cytokines such as IL-1, TNF alpha, IL-10 and TGF beta, decreased and an anti-inflammatory cytokine IL-4 increased after spinal cord injury in mice transplanted hMSCs. We revealed that hMSCs regulated anti-inflammatory effect through pituitary adenylate cyclase activating peptide (PACAP). We also reported that chemokine CCL5 and its receptor, CCR1 and CCR5, increased through 14th day after injury by RT-PCR using mRNA of injured tissues. It suggested that CCL5 was involved in chronic inflammatory phase and It was important for the treatment period.
|
